New drug ICP-332 tested in healthy people for safety first
NCT ID NCT06530966
First seen Apr 15, 2026 · Last updated May 09, 2026 · Updated 3 times
Summary
This early-phase study tested the safety and tolerability of a new drug called ICP-332 in 24 healthy adults aged 18 to 55. Participants received either the drug or a placebo, and researchers monitored for side effects and changes in vital signs, lab values, and heart activity. The goal was not to treat any disease but to gather essential safety information before further studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pharmaron CPC Inc.
Baltimore, Maryland, 21201, United States
Conditions
Explore the condition pages connected to this study.